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Th   e estimated cost of bringing a new drug to the clinic 
has increased to ~$1.2 billion, up from ~$800 million in 
2003 [1]. Pharmaceutical companies face their largest 
losses when drugs fail late, in phase III trials and at the 
post-marketing stage [2]. Th   e majority of drug recalls in 
the past 40 years have been due to cardiotoxicity (19% of 
withdrawals, including Micturin, Fen-phen, Seldane, 
Vioxx, Avandia), hepatotoxicity (26% of withdrawals, 
including Ananxyl, Alredase, Tasmar, Rezulin, Survector, 
Trovan, Cylert, Exanta, Prexige), or unpredicted adverse 
eﬀ   ects of drug interactions (for example, Posicor, 
Hismanal) [3,4]. Drug toxicities that pass through pre-
clinical and clinical studies may result in deaths, and are 
highly costly. A notable example is Vioxx that has cost 
Merck over $5 billion in criminal and civil settlements, 
and has been linked to more than 27,000 deaths [5].
Existing preclinical models can provide a critical 
window into human physiology for determining drug 
safety and eﬃ   cacy. However, as many as 60% of late-stage 
drug development failures are due to unforeseen absorp-
tion, distribution, metabolism, excretion, and toxicity 
proﬁ   les that might have been predicted if models of 
human liver tissue were available earlier in drug develop-
ment [6]. Likewise, existing heart models of cardiotoxicity 
do not always correlate with clinical risks. For example, 
preclinical hERG assays are quite helpful in identifying 
compounds with action potential prolongation, but are 
not suﬃ   cient for predicting clinical QT-proarrhythmia 
[4]. Human microtissues platforms are now under 
develop  ment to improve our capability for disease 
modeling [7,8] and toxicology studies [9,10].
Overall, the lack of predictive drug-screening systems 
is a critical barrier to bringing drugs to patients. In spite 
of major advances, existing culture systems still lack 
many of the structural and signaling features of native 
tissues, the temporal and spatial sequences of molecular 
and physical regulatory factors, and the dynamic forces 
and systemic factors provided by blood circulation. Even 
in the best culture settings where distinct cell types of a 
speciﬁ  c organ system are co-cultured to promote tissue-
speciﬁ   c transport and signaling, the eﬀ  ects  of  organ–
organ interactions, metabolic/oxygen gradients, and 
cellular traﬃ   cking through tissues are still not included 
[9,11]. Also, engineered tissues have only scratched the 
surface in attempting to model human disease. Animal 
models often fail to capture human-speciﬁ  c features, and 
oﬀ   er only limited control of and insight into speciﬁ  c 
mechanisms. As a result, disconnect between in vitro
studies, translational animal models, and human clinical 
studies decreases the eﬀ   ectiveness of the resulting 
therapeutic strategies. Functional human tissue units, 
engineered to combine biological ﬁ  delity with the use of 
high-throughput platforms and real-time measurement 
of physiological responses, would be transformative to 
drug screening and predictive modeling of disease.
Modeling integrated human physiology in vitro is a 
formidable goal that has not been reached with any of the 
existing cell/tissue systems. Tissue engineering is now 
becoming increasingly successful in more authentically 
representing the actual environmental milieu of 
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Our project team is developing an integrated 
microphysiological platform with functionally 
connected vascular, liver and cardiac microtissues 
derived from a single line of human pluripotent stem 
cells. The platform enables functional representation 
of human physiology in conjunction with real-time 
biological readouts (via imaging and homologous 
reporters for all three cell phenotypes) and 
compatibility with high-throughput/high-content 
analysis. In this paper, we summarize progress made 
over the fi  rst year of the grant.
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in providing real-time insights into cellular and morpho-
genic events. While it is unreasonable to expect three-
dimensional tissue models to exactly match native 
tissues, the models can still recapitulate certain physio-
logical functions and be used to investigate the eﬃ   cacy, 
safety and mode of action of therapeutic agents. Instead 
of attempting to achieve the entire complexity of an 
organ, we seek to identify the simplest functional tissue 
unit allowing predictive in vitro studies of normal 
physiology and disease.  Such a minimally functional 
tissue unit would replicate the tissue-speciﬁ  c architecture 
(as a basis for function in most tissues) and a subset of 
most relevant functions.
Derivation of multiple microtissues (such as heart, 
liver, vasculature) starting from a single population of 
human induced pluripotent stem (iPS) cells allows us to 
reach into a large genotype pool and use both the healthy 
cells and cells with genetic mutations for drug screening 
and modeling of disease. Modular microtissue platforms 
can then capture the salient features of multiple human 
tissues, by integrating tissue-speciﬁ   c cues within the 
micro  tissue unit (to induce physiologic cell function) 
with the vascular network (to assemble miniature yet 
functional tissue modules). Th  ese microphysiological 
plat  forms can be further interfaced with functional imag-
ing, to enable real-time monitoring of physiological res-
ponses at molecular, cellular and tissue levels. Such 
interactive microtissue systems oﬀ   er enormous com-
plexity and diversity of responses to drugs and disease 
that can be modeled (for example, cardiotoxicity of drugs 
metabolized by liver in a diverse genotype pool of 
patients, inﬂ   ammation, combinations of disease geno-
types and disease environments).
We propose that human tissues with utility for micro-
physiological studies need to combine biological com-
plexity (multicellular composition, normal and disease 
phenotypes, tissue-speciﬁ   c architectures, vascu  lari-
zation, normal human biology) and compatibility with 
high-throughput screening platforms (small size, easy 
handling, online readouts). With this in mind, we are 
developing integrated tissue platforms that faithfully 
represent the human vascular network, metabolizing 
liver lobule and working cardiac muscle
Project goals and objectives
In the current (UH2) phase of work, we are establishing 
iPS cell-based vascular, liver and cardiac microtissues 
providing tissue-speciﬁ  c architectures with an integrated 
vascular network, microﬂ  uidic endothelialized connec-
tions between the tissue modules, functional represen-
tation of human biology of health, injury and disease 
(real-time biological readouts), and compatibility with 
high-throughput multi-tissue platforms for studies of 
drug toxicity and over long periods of time (≥4 weeks). 
Th   e work is being done using iPS cells (to provide a large 
diversity of normal and disease genotypes) with non-
destructive monitoring of the tissue architecture and 
function (for real-time insights into the progression of 
biological responses). In the subsequent (UH3) phase of 
work, we aim to deploy an integrated cardiac–hepatic–
vascular platform and demonstrate its utility for predic-
tive studies of human physiology.
Towards these goals, we are pursuing a set of co-
ordinated aims with constant feedback and monitoring of 
the milestones. Aim  1 is to develop cell-type speciﬁ  c 
labeling and sensing systems for online assessment of 
tissue architecture and cell function. Aim 2 is to develop 
a perfusable branching vascular network serving as a 
model of the vascular bed and for assembling 
vascularized liver and cardiac tissues. Aim 3 is to develop 
a liver module by assembling hepatic microtissues in 
hydrogel around the vascular tree. Aim 4 is to develop a 
cardiac module by assembling matured cardiac micro-
tissues in hydrogel around the vascular tree. Aim 5 is to 
conduct studies of disease susceptibility, for the 
individual tissue modules and in the multi-tissue 
platform. Aim 6 is to investigate human physiology and 
disease in multi-tissue platforms. Th  is way, we aim to 
develop a new technology for studies of drugs in human 
tissue models. If successful, the proposed approach 
would radically enhance the translation of drug discovery 
into human applications.
Summary of current progress
Representative results for the ﬁ   rst project year are 
summarized in Figures 1 and 2, and in several publica-
tions [8,10,12-27].
Induced pluripotent stem reporter lines of endothelial 
cells, cardiomyocytes and hepatocytes
Our laboratories have continued interest and strong 
expertise in biophysical regulation of the fate and 
function of stem cells and their diﬀ  erentiated progeny 
using molecular, cellular, matrix-derived and physical 
factors. We will continue to use these approaches for 
directed diﬀ   erentiation of stem cells into endothelial, 
cardiac and hepatic lineages, and maturation of the 
resulting diﬀ  erentiated cells.
To create clinically relevant human tissue models, we 
aim to generate all cell types needed for tissue con-
struction from the same batch of iPS cells. In order to 
allow use of molecular and functional imaging and study 
physiological processes at multiple hierarchical levels and 
in real time, we are now incorporating biosensors 
(reporters) into the iPS cells to monitor speciﬁ  c  cell 
phenotypes in culture (for example, distinguish between 
endothelial cells and cardiomyocytes), and to monitor 
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established culture conditions for routine and robust 
generation of endothelial cells that exhibit co-expression 
of cell surface markers (that is, CD31, VE-cadherin) and 
functional properties (endothelial nitric oxide synthase 
production, tube formation) from multiple iPS cell lines 
with at least 10 to 40% eﬃ   ciency [19]. We have recently 
adopted the culture conditions used by the Bhatia and 
Vunjak-Novakovic laboratories to maintain the speciﬁ  c 
iPS cell line that we are using to create the reporter lines 
(iPS C2a). We are now optimizing the conditions for 
endothelial cell-speciﬁ  c diﬀ  erentiation of this speciﬁ  c cell 
line. We are now generating reporter cell lines using Talens 
[28] for homologous recombination in the iPS C2a cells 
(iPS endothelial cells, VEcad/GFP; iPS cardio  myo  cytes, 
beta-MHC/FRFP; and iPS hepatocytes, CYP3A4/RFP).
Perfusable vascular networks
By this time, we have developed a general approach to 
rapidly construct perfusable vascular networks to 
Figure 1. HeLiVa platform design. (A) Modular design of the culture platform, with interlocking culture chambers (the same external design, 
diff  erent internal designs) connected to each other and the microfl  uidic channels for medium perfusion. A single top and bottom plate are 
formed by connecting the individual chamber tops and bottoms, and sealed together to form a culture platform. (B) Chamber design for a cardiac 
microtissue forming around a sugar lattice (that dissolves to leave vascular network channels) and two posts (designed to subject cardiac tissue 
to mechanical strain, and also to serve for optical measurement of force generation by the cells), between two electrodes for electrical stimulation 
(the whole row of chambers shares a single pair of electrodes). (C) Chamber design for a liver microtissue, also forming around a sugar lattice (that 
dissolves to leave vascular network channels). For all chambers, ports are provided for fl  uid inlets and outlets and sample retrieval. (D) Platforms 
with cardiac microtissues. (E) Liver chamber. (F) Sugar lattices. (G) Contractile cardiac microtissue grown from induced pluripotent stem (iPS) cells 
after 4 weeks of cultivation. (H) Even propagation of electrical signals through cardiac tissue obtained from human endothelial stem cells cultured 
in a hydrogel derived from porcine heart tissue, measured by printed microelectrodes. (I) Vascular channels were generated by three-dimensional 
printing of sugar-based sacrifi  cial fi  laments and coated by human endothelial cells. (J) The endothelium forms a tight barrier between lumen and 
interstitium (not shown), and when exposed to a gradient of angiogenic factors undergoes angiogenic sprouting that leads to new perfusable 
vascular networks. (K) Mature sprout stained for podocalyxin (red). Below are cross-sections of the tip cell (showing no lumen or spatial podocalyxin 
localization) and stalk (showing podocalyxin staining at the apical side). (L) Neovessel. (M) iPS cell-derived endothelial cells cultured on an OP9 
feeder layer, staining for VE-cadherin (VE-Cad) and CD31 (merged image) and 4’,6’-diamino-2-phenylindole (DAPI; blue). (K), (L) Images reproduced 
with permission [23].
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three-dimensionally the rigid ﬁ   lament networks of a 
carbohydrate glass, and used them as a cytocompatible 
sacriﬁ   cial template in engineered tissues containing 
living cells to generate networks lined with endothelial 
cells and perfused with blood under high-pressure 
pulsatile ﬂ   ow [20-23]. We have developed several 
methods to generate channel architectures within matrix 
scaﬀ   olds using either sacriﬁ  cial  ﬁ   laments printed in 
sugars [20] or gelatin [22], or using needles that are 
withdrawn from the material [23]. In all of these cases, 
seeding human endothelial cells into these channels 
results in the formation of well-developed endothelium 
that exhibits characteristics of functional endothelium. 
We have observed intraluminal ﬂ  ows at high rates relative 
to extraluminal ﬂ  ow, and identiﬁ  ed tight junctions that 
were permeable to transluminal leakage only when cells 
are exposed to vasoactive permeating factors.
To facilitate assembly of the HeLiVa platform, we have 
also developed a mechanism that allows easy plug-in of 
input and output microﬂ  uidic tubing to ultimately drive 
the perfusion within the vascular bed and connect 
multiple organ systems [22]. In parallel, we have begun to 
explore methods to integrate the vascular perfusion 
approaches with the cardiac microtissue platform.
Liver microtissues
We initially focused on generating hepatic microtissues 
from cryopreserved human hepatocytes, and then 
extended the established methods to a variety of cell 
types including iPS cell-derived hepatocytes. An integral 
part of this eﬀ  ort was the development of platforms for 
scalable control of tissue architectures [24,27]. To help 
maintain hepatocyte phenotype, we ﬁ  rst co-cultured the 
primary hepatocytes with supportive ﬁ  broblasts by seed-
ing the two cell types into an array of pyramidal 
Figure 2. Screening approaches. (A) D iff  erentiation of induced pluripotent stem (iPS) cells into hepatocytes, by recapitulating normal stages of 
liver development (the same strategy is pursued for iPS cardiomyocytes). Hepatocyte-like cells derived this way still have a fetal phenotype. (B) To 
mature the cells, we designed a small molecule screen where we treated iPS cell-derived hepatocytes (iHeps) from day 20 of the diff  erentiation for 
9 days, and found a few molecules that improved the maturation of iPS cell-derived hepatocytes. (C) Results are for the top hit of small-molecule 
screening. (D) Aggregates of cryopreserved primary human hepatocytes (~5 hepatocytes/5 fi  broblasts per aggregate) are microfl  uidically 
encapsulated into uniform droplets in a microfl  uidic device, and photopolymerized to form microtissues. (E) Viable cells in liver microtissues (scale 
bar = 100 μm). bFGF, basic fi  broblast growth factor; BMP4, bone morphogenetic protein 4; ELISA, enzyme-linked immunosorbent assay; HGF, 
hepatocyte growth factor; OSM, oncostatin M; (C) Image reproduced with permission [16].
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blasts (approximately ﬁ   ve hepatocytes and ﬁ  ve  ﬁ  bro-
blasts) in each microwell formed multicellular aggregates 
over 24 hours. Th   ese primary hepatocyte aggregates were 
then removed, encapsulated in microﬂ  uidically generated 
droplets of polyethylene glycol diacrylate prepolymer, 
and photopolymerized to form hepatocyte-laden 
hydrogel microtissues. Resulting liver microtissues are 
viable as evaluated by live–dead staining, and exhibit 
stable phenotypic function, secreting albumin for over 
2 weeks. Towards an iPS cell-derived liver module, we 
have generated morphologically identiﬁ  able hepatocytes 
from human iPS cells with diﬀ  erentiation  eﬃ   ciencies 
>90%, as quantiﬁ   ed by albumin and α1-antitrypsin 
immuno ﬂ  uorescence, and identiﬁ  ed small molecules for 
human hepatocyte expansion and iPS cell diﬀ  erentiation 
[16]. iPS cell-derived hepatocytes were additionally 
validated through characterization of urea production, 
albumin and α1-antitrypsin secretion, and phase I drug 
metabolism activity. Notably, liver microtissues were 
successfully used to model hepatitis C infection [25].
Heart microtissues
We established protocols for diﬀ  erentiation of iPS cell lines 
into contractile cardiomyocytes, for three lines of iPS cells. 
Over the last 6 months we focused on one speciﬁ  c line, iPS 
C2a, which is now shared between all four laboratories. 
After systematically investigating several variations of 
staged molecular induction in three diﬀ  erent  settings 
(embryoid bodies, monolayers and pseudo-monolayers), 
we came to our protocol of choice that yields ~65% of 
diﬀ  erentiated cardiomyocytes (as evaluated by Troponin 
staining and contractile function). By micromanipulation 
(picking of beating areas), the yield of the protocol can be 
increased to >80%, as com  pared with our target go–no–go 
criterion of >30%. Simple microﬂ  uidic platforms [12,27] 
were instrumental in the development of protocols for 
directed diﬀ  er  en  tiation of stem cells.
Th   e resulting iPS cardiomyocytes, although functional, 
remain immature. To promote cardiomyocyte matura-
tion, we applied electromechanical conditioning, follow-
ing molecular induction (7 days, 5 V/cm, 2 ms square 
waves, frequency = 0, 0.5 Hz, 1 Hz, 2 Hz). Th  e  protocols 
were fully established for human embryonic stem cell 
cardiomyocytes and are now translated to iPS C2a 
cardiomyocytes. Electrical stimulation increased the 
strain of contractions in cardiac microtissues. In parallel, 
the contractions became synchronized and the strain 
generated by cardiac microtissues increased as the 
stimulation frequency increased.
Platform integration
We have developed the second working prototype of our 
platform, in which we have tested the assembly and 
perfusion of cardiac microtissues formed from iPS C2a 
cells, and recently started testing with iPS hepatocytes. 
Th   e culture chambers have a space for the formation of 
cardiac microtissues from a suspension of iPS cardio-
myocyte micro-aggregates in hydrogel. Th  e hydrogel 
forms around the sugar lattice, between two electrodes, 
and around two posts (that at the same time stretch the 
cardiac microtissues, and enable optical measurement of 
the force generated by the cells from the deﬂ  ection of the 
posts). To design the posts (material composition, geo-
metry) we conducted analyses of the strain distribution 
in contracting cardiac organoids. We are now assembling 
subsections of the integrated microphysiologic platform, 
for further testing and for obtaining feedback to the 
individual chamber design.
Future directions
We have established methods to derive, starting from the 
same population of iPS cells (using the line C2a as the 
main experimental model), functional endothelial cells, 
cardiomyocytes and hepatocytes of high ﬁ  delity. We have 
also developed methods for maturation of diﬀ  erentiated 
cells, using small molecules (for hepatocytes) and 
physical signals (for cardiomyocytes). Th  e  ﬁ  rst prototypes 
of microﬂ   uidic platforms for the formation and culti-
vation of vascular, cardiac and hepatic microtissues are 
now being used to demonstrate utility of human iPS cell-
derived microtissues for physiological and pharmaco-
logical studies. Our immediate goals are to reﬁ  ne our 
microtissues by incorporating the vascular bed, to 
establish modular multi-tissue platforms, and to use 
these platforms in studies of interactive responses of 
cardiac, vascular and hepatic microtissues to pharmaco-
logical agents, physiological and pathological stimuli.
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